Detection of
EPHI, Ethiopian Public Health Institute
EPTB, extrapulmonary tuberculosis
MDR, multidrug resistance
MTB, Mycobacterium tuberculosis
MTBC, Mycobacterium tuberculosis complex
Mycobacterium tuberculosis
NTRL, National Tuberculosis Reference Laboratory
PTB, pulmonary tuberculosis
RIF, rifampicin
RR-TB, rifampicin-resistant tuberculosis
SPSS, Statistical Package for Social Sciences
TB, tuberculosis
WHO, World Health Organization
Xpert MTB/RIF
frequency
rifampicin resistance
Journal
IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
27
07
2022
revised:
31
08
2022
accepted:
01
09
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
This study aimed to determine the frequencies and trends of Data were collected retrospectively from patient registries. Laboratory-based data were extracted from the national tuberculosis (TB) referral laboratory database. All patients referred to the National Tuberculosis Reference Laboratory (NTRL) for TB diagnosis from all over the country between March 1, 2014 and September 30, 2021, and tested using the Xpert MTB/RIF assay, were included. The extracted data were entered into a Microsoft Excel sheet and analyzed by Statistical Package for Social Sciences (SPSS) version 23. Among a total of 13 772 individuals tested using the Xpert MTB/RIF assay, the majority (8223; 59.7%) were males, and 48.5% (6678) of the individuals were aged between 15 and 39 years. The frequency of TB and RR-TB remains high in the study setting. RR-TB was found to have a statistically significant association with previous anti-TB medication treatment. As a result, improving treatment adherence in recognized instances could assist in preventing MTB and RR-TB cases.
Identifiants
pubmed: 36247095
doi: 10.1016/j.ijregi.2022.09.001
pii: S2772-7076(22)00113-8
pmc: PMC9556786
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97-103Subventions
Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Informations de copyright
© 2022 The Author(s).
Références
N Engl J Med. 2010 Sep 9;363(11):1005-15
pubmed: 20825313
Int J Tuberc Lung Dis. 2012 Jun;16(6):805-11
pubmed: 22390880
Infect Drug Resist. 2020 May 21;13:1507-1516
pubmed: 32547120
Infect Drug Resist. 2020 Oct 29;13:3863-3872
pubmed: 33149631
Infect Dis Ther. 2021 Sep;10(3):1299-1308
pubmed: 33950463
BMC Infect Dis. 2019 Apr 4;19(1):307
pubmed: 30947695
PLoS One. 2018 Sep 13;13(9):e0203063
pubmed: 30212505
Tuberculosis (Edinb). 2015 May;95(3):315-20
pubmed: 25814302
PLoS One. 2020 Nov 4;15(11):e0240361
pubmed: 33147218
Open Forum Infect Dis. 2021 Jan 19;8(4):ofab025
pubmed: 33884274
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419827174
pubmed: 30791749
Int J Mycobacteriol. 2019 Apr-Jun;8(2):132-137
pubmed: 31210154
Infect Drug Resist. 2020 Aug 20;13:2911-2919
pubmed: 32903905
BMC Infect Dis. 2019 Apr 11;19(1):316
pubmed: 30975090
New Microbes New Infect. 2017 Jul 13;19:117-120
pubmed: 28794886
Infect Drug Resist. 2020 Oct 06;13:3451-3459
pubmed: 33116664
PLoS One. 2016 Mar 07;11(3):e0150646
pubmed: 26950547
New Microbes New Infect. 2021 Jan 20;40:100841
pubmed: 33664961
Lancet Glob Health. 2014 Aug;2(8):e453-9
pubmed: 25103518
Access Microbiol. 2021 Feb 11;3(3):000202
pubmed: 34151157
J Int Med Res. 2017 Apr;45(2):816-822
pubmed: 28351283
Open Forum Infect Dis. 2019 Feb 22;6(3):ofz075
pubmed: 30949526
Infect Drug Resist. 2021 Apr 07;14:1335-1341
pubmed: 33854346
BMC Res Notes. 2017 Jan 3;10(1):8
pubmed: 28057041
PLoS One. 2018 Jul 16;13(7):e0200755
pubmed: 30011319
J Clin Microbiol. 2010 Jul;48(7):2495-501
pubmed: 20504986
Biomed Res Int. 2018 Aug 07;2018:8207098
pubmed: 30159328
Pan Afr Med J. 2017 Aug 08;27:260
pubmed: 29187929
Heliyon. 2019 Jul 16;5(7):e02096
pubmed: 31360790
PLoS One. 2017 Oct 9;12(10):e0186139
pubmed: 29016684
BMC Public Health. 2011 Mar 08;11:154
pubmed: 21385458